• Skip to main content
kleo_logo_final_Bio
  • About
    • Company
  • Pipeline and Programs
    • Pipeline
    • COVID-19 Programs
    • Multiple Myeloma Programs
  • Our Science
    • ARMs
    • ARM NK Combo
    • MATEs
  • News & Events
  • Partnerships

New Pipeline

PIPELINE

Screen Shot 2020-06-27 at 5.18.23 PM
Discovery
Validation/Optimization
In Vivo POC
IND Studies
Phase 1
Platform: Multiple Myeloma (CD38 Targeting)
%
Candidate/Program: KP1237 (ARM™) + Autlogous NK cells • Patient Population: Post Transplant

 

 

%
Candidate/Program: KP1237(ARM™) • Patient Population: Darzalex® R/R

 

 

%
Candidate/Program: KP1237 (ARMTM) + Allogeneic NK cells • Patient Population: Post-Transplant • Collaborator: Celularity, GC LabCell
Platform: COVID-19 (Spike Protein Targeting)
%
Candidate/Program: COVID-19 MATETM HGM • Patient Population: Prophylactic or Hospitalized
%
Candidate/Program: COVID-19 ARMTM • Patient Population: Hospitalized
%
Candidate/Program: COVID-19 ARMTM • Patient Population: Hospitalized Collaborator: Celularity, GC LabCell

About

  • Company

Our Pipeline

Our Technologies

  • ARMs
  • ARM NK Combo
  • MATEs

Careers

News & Events

Partnerships

© 2019 Kleo Pharmaceuticals. All Rights Reserved.